Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial

Dan-Yu Lin; Lindsey R Baden; Hana M El Sahly; Brandon Essink; Kathleen M Neuzil; Lawrence Corey; Jacqueline Miller; COVE Study Group

doi:10.1001/jamanetworkopen.2022.15984

Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial

JAMA Netw Open. 2022 Jun 1;5(6):e2215984. doi: 10.1001/jamanetworkopen.2022.15984.

Authors

Dan-Yu Lin¹, Lindsey R Baden², Hana M El Sahly³, Brandon Essink⁴, Kathleen M Neuzil⁵, Lawrence Corey⁶, Jacqueline Miller⁷; COVE Study Group

Collaborators

COVE Study Group:
Moni B Neradilek, Holly Janes, Weiping Deng, Honghong Zhou

Affiliations

¹ Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill.
² Brigham and Women's Hospital, Boston, Massachusetts.
³ Department of Medicine, Baylor College of Medicine, Houston, Texas.
⁴ Meridian Clinical Research, Omaha, Nebraska.
⁵ Department of Medicine, University of Maryland, Baltimore.
⁶ Fred Hutchinson Cancer Research Center, Seattle, Washington.
⁷ Moderna, Cambridge, Massachusetts.

Abstract

This cohort study assesses the durability of protection against symptomatic COVID-19 among participants of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine trial.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

2019-nCoV Vaccine mRNA-1273*
COVID-19* / prevention & control
Clinical Trials as Topic
Humans

Substances

2019-nCoV Vaccine mRNA-1273

Abstract

Publication types

MeSH terms

Substances

Grants and funding